IL-21 fusion protein for improving humoral immune level of subunit vaccine and preparation method of IL-21 fusion protein
Through the binding of IL-21-Fc fusion protein with antigen and aluminum adjuvants, it is used in subunit vaccines, solving the limitations of existing adjuvants in immune responses, significantly improving the effectiveness of humoral and cellular immune responses, and improving the The safety of the vaccine.
Patent Information
- Application Number
- CN202411091624.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
Existing vaccine adjuvants have limitations in inducing a strong and lasting immune response, especially aluminum adjuvants can only cause weak cellular immune responses, and may be accompanied by adverse reactions, and there are limited types, so we need to find safe and effective alternatives. Adjuvant to enhance immune response.
IL-21-Fc fusion protein is used as an adjuvant, and is used to prepare subunit vaccines by binding to antigen and aluminum adjuvant. The specific steps include cloning the fragment of IL-21 from the mouse genome to construct pTT5-IL-21- Fc recombinant vector, expressed and purified the IL-21-Fc protein and mixed with the SARS-CoV-2 spike S protein RBD region and aluminum adjuvant for immunization.
IL-21-Fc significantly improves humoral immune response, enhances the titer of antigen-specific IgG antibodies, promotes germinal center reactions and proliferation and differentiation of B cells, and enhances cellular immune responses, including CD4+ and CD8+ in the spleen and lungs. T cells are activated and have higher safety relative to exogenous substances.
Smart Images

Figure CN118994415A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of bioengineering and immunotechnology, and in particular to an IL-21-Fc fusion protein for improving the humoral immunity level of a subunit vaccine and a preparation method thereof, as well as an application of the fusion protein in a protein subunit vaccine. Background Art
[0002] Interleukin 21 (IL-21) and its receptor IL-21R were first discovered in 2000. Interleukin 21 is a cytokine with a wide range of pleiotropic effects that can affect the differentiation and function of lymphocytes and myeloid cells, and plays an important role in anti-tumor, antiviral responses, autoimmune diseases, and inflammatory diseases. In vivo, IL-21 signals can stimulate and activate IL-21 receptors, which form heterodimers with the cytokine receptor γ chain (γc chain), thereby activating the JAK-STAT signaling pathway. IL-21 is mainly expressed by natural killer T cells (NKT cells), T follicular helper cells (T fh ) and TH17 cells, and many other lymphocyte populations also produce lower levels of IL-21, and act on a variety of lymphocytes and myeloid cells, as well as epithelial cells, with pleiotropic effects on both innate and adaptive immune responses. IL-21 can work with IL-7 and IL-15 to promote CD8 + Proliferation and survival of T cells. As an important target cell of IL-21, B cells can produce multiple responses to IL-21 signals, such as cooperating with IL-4 to promote IgG production, driving the class conversion to IgG1 and IgG3, and B cell differentiation into plasma cells. IL-21 also affects the formation and polarization of germinal centers. The efficient response of B cells and germinal centers to antigens is the basis for the generation of lasting humoral immunity, so the effect of IL-21 on humoral immunity and vaccine effect is also the focus of the present invention.
[0003] Vaccines are a powerful tool for controlling microbial infections and preventing epidemics, and are also one of the most economical and effective ways to prevent and treat infectious diseases. Vaccines have successfully eradicated smallpox virus and effectively prevented and controlled the spread of once-lethal pathogens such as polio virus, human papillomavirus (HPV) and hepatitis B virus (HBV). Vaccines refer to biological products made from various pathogenic microorganisms for vaccination. Traditional vaccines are mainly divided into inactivated vaccines and attenuated vaccines. In recent years, with the development of disciplines such as immunology, microbiology, and bioengineering, protein subunit vaccines, mRNA vaccines, and viral vector vaccines have gradually been put into experiments and applications. Compared with conventional vaccines, subunit vaccines have good safety, but also show poor immunogenicity. Adjuvants are needed to achieve effective antigen delivery and improve the level of immune response. Adjuvants are a class of non-specific auxiliary substances that can be injected into the body together with antigens or pre-injected into the body, which can enhance the immune response to vaccine antigens.
[0004] At present, the vaccine adjuvants that can be used in humans mainly include aluminum adjuvants, water-in-oil emulsions (such as AS03, MF59), liposomes, and some TLR agonists (such as CPG), and the number and types are very limited. Among them, the most widely used aluminum adjuvant mainly induces humoral immune responses and promotes the production of IgG1, but can only cause weak cellular immune responses and may be accompanied by adverse reactions such as fever and local redness and swelling. Therefore, it is necessary to find other safe and effective adjuvants to induce strong and lasting immune responses. Cytokines play an important role in inducing innate immunity and promoting adaptive immunity, so they are also regarded as potential adjuvants to be screened experimentally. Summary of the invention
[0005] In view of this, one of the objects of the present invention is to provide a use of IL-21-Fc protein in preparing a subunit vaccine, characterized in that the amino acid sequence of the IL-21-Fc protein is as shown in SEQ ID NO:4.
[0006] The invention relates to use of the IL-21-Fc protein in the preparation of a subunit vaccine, wherein the subunit vaccine is a SARS-CoV vaccine.
[0007] Another object of the present invention is to provide a method for preparing IL-21-Fc protein, wherein the amino acid sequence of the IL-21-Fc protein is as shown in SEQ ID NO:4.
[0008] To achieve the above object, the present invention provides a method for preparing IL-21-Fc protein, characterized in that the protein coding sequence is derived from the mouse genome, has a TEV restriction site and an Fc tag, and the preparation steps are as follows:
[0009] A. Using mouse spleen cDNA library as a template, clone and amplify the IL-21 target fragment with linearized pTT5-Fc vector homologous sequences at both ends;
[0010] B. Connect the target fragment described in A to the pTT5-Fc expression vector by Gibson assembly to construct the pTT5-IL-21-Fc recombinant vector;
[0011] C. amplify the pTT5-IL-21-Fc recombinant vector described in B, transiently transfect into the eukaryotic expression host HEK293F cells by PEI, and express for 4 days;
[0012] D. Collect the culture supernatant, purify the fusion protein IL-21-Fc in the culture supernatant using protein A column affinity chromatography, and concentrate using a 10KDa ultrafiltration tube to obtain IL-21-Fc.
[0013] Furthermore, the primer sequence for amplifying the IL-21 gene fragment in step A is:
[0014] Upstream primer:
[0015] AAGTCAAGCTGCTCTCTGGGCGTCGACCATAAATCAAGCCCCCA AGGGC, as shown in SEQ ID NO: 1;
[0016] Downstream primer:
[0017] GGAAATAAAGATTCTCAGAACCTCTAGAGGAGAGATGCTGATGA ATCATCTTTTGAAGG, as shown in SEQ IDNO:2.
[0018] Furthermore, in step A, the IL-21 gene sequence is shown as SEQ ID NO:3, and the IL-21-Fc protein amino acid sequence is shown as SEQ ID NO:4.
[0019] Furthermore, the preparation method comprises obtaining the target IL-21 fragment by amplification, wherein the C-terminus of the target IL-21 fragment has an extracellular secretion signal peptide, and the N-terminus is connected to a TEV enzyme recognition site and an Fc tag.
[0020] Furthermore, the Gibson assembly connection procedure in step B is 50°C for 60 min, and the system contains 2×T5 exonuclease, linearized vector pTT5-TEV-Fc and target gene fragment IL-21, wherein the ratio of the inserted fragment IL-21-Fc to the linearized vector substance is 4:1.
[0021] Furthermore, the recombinant vector successfully constructed by sequencing and screening in step C is subjected to plasmid extraction and cell transfection. The HEK293F cells used are suspension cells, which are cultured in a serum-free 293 special medium containing penicillin-streptomycin double antibodies to a density of 2×10 6 -3×10 6 For each 100 mL of HEK293F cells, 0.1 mg of plasmid, 0.4 mg of PEI (1 mg / mL) and 5 mL of high-glucose DMEM medium were added. After transfection, the cells were placed at 37°C with 5% CO 2 , and cultured in a shaking incubator at 120 rpm for 4 days.
[0022] Furthermore, the centrifugation parameters for collecting the culture supernatant in step D are 4°C, 5000 rpm, 20 min; and when purifying the protein by affinity chromatography on a protein A column, the flow rate for column loading and elution is 3 mL / min.
[0023] Another object of the present invention is to provide an immune complex or subunit vaccine, characterized in that it comprises an antigen, an aluminum adjuvant and an IL-21-Fc protein, and the amino acid sequence of the IL-21-Fc protein is shown in SEQ ID NO:4.
[0024] Furthermore, in the immune complex or subunit vaccine of the present invention, the antigen is the RBD region of the SARS-CoV-2 spike S protein.
[0025] Furthermore, in the immune complex or subunit vaccine of the present invention, the aluminum adjuvant is aluminum hydroxide adjuvant.
[0026] In a specific embodiment, the immune complex or subunit vaccine of the present invention is characterized in that the weight ratio of the antigen to the aluminum adjuvant to the IL-21-Fc protein is 1:50-100:200.
[0027] In a specific embodiment, the immune complex or subunit vaccine of the present invention is characterized in that the immune complex or subunit vaccine is administered three times with an interval of 14 days.
[0028] The present invention also provides a kit, which comprises the above-mentioned immune complex or subunit vaccine.
[0029] The present invention has the following advantages and beneficial effects:
[0030] 1. IL-21-Fc in the present invention enhances humoral immune response, increases the titer of antigen-specific IgG antibodies, and enhances the ability of vaccine-induced serum antibodies to bind to antigens.
[0031] 2. IL-21-Fc in the present invention promotes germinal center reaction and proliferation and differentiation of B cells, significantly increases the proportion of germinal center B cells in the spleen and the number of antigen-specific germinal center B cells, and increases the proportion of antigen-specific memory B cells in the bone marrow.
[0032] 3. IL-21-Fc in the present invention enhances cellular immune response, including increasing the proportion of follicular helper T cells in the spleen and CD4 + T cells and CD8 + Enhanced T cell activation.
[0033] 4. The present invention uses cytokine IL-21 as an adjuvant in a protein subunit vaccine. IL-21 itself is a component of the immune response of an organism and has greater safety advantages than other exogenous substances.
[0034] 5. The present invention realizes the expression and purification of the fusion protein IL-21-Fc and provides a potential method for preparing the protein IL-21.
[0035] 6. The present invention uses a eukaryotic HEK293F (human embryonic kidney epithelial cell) expression system, which has the advantages of simple operation and short expression cycle; and the IL-21 of the present invention comes from mice and is expressed using an expression system also from mammals, and the modification of the protein is closer to the natural state than the prokaryotic expression system. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 The figure is a recombinant vector plasmid map of pTT5-IL-21-Fc, in which the inserted target fragment is located between the restriction sites of Sail 1 and Xba1.
[0037] Figure 2 This is the PCR electrophoresis result of the IL-21 target fragment with linearized pTT5-Fc vector homologous sequences at both ends obtained by cloning and amplification using mouse spleen cDNA library as a template. The first lane is 250bp+DNA molecular weight standard, the second lane is IL-4 PCR product, and the fourth lane is IL-21 PCR product.
[0038] Figure 3 This is a verification diagram of the sequencing results of the recombinant vector pTT5-IL-21-Fc.
[0039] FIG4 is a diagram of protein purification of IL-21-Fc, wherein Figure 4A This is the peak diagram of protein A column elution. %B refers to the proportion of 0.1M acetic acid in the eluent. Figure 4B It is the SDS-PAGE electrophoresis diagram of protein IL-21-Fc, wherein the first lane is the protein Marker, and the second to sixth lanes are the fusion protein IL-21-Fc.
[0040] Figure 5 Detection results of RBD-specific antibody IgG in the serum of mice immunized with IL-21-Fc mixed with RBD and aluminum adjuvant after intraperitoneal injection.
[0041] FIG6 shows the detection results of spleen of mice immunized with IL-21-Fc or IL-4-Fc mixed with RBD and aluminum adjuvant after intraperitoneal injection; Fig. 6A Germinal center B cells (GCB), RBD-specific germinal center B cells (RBD + The number of GCB, RBD-specific memory B cells (RBD + The ratio of MBC) and the number of plasma cells (PC); Figure 6B Follicular helper T cells (T fh) and activated CD4 + T cells (CD69 + and PD1 + ) ratio comparison, activated CD8 + T cells (CD69 + and PD1 + ) ratio comparison.
[0042] Figure 7 The results of bone marrow examination of mice immunized with IL-21-Fc or IL-4-Fc mixed with RBD and aluminum adjuvant after intraperitoneal injection showed that RBD-specific memory B cells (RBD + The percentage of MBC, the percentage of plasmablasts (PB) and the percentage of plasma cells (PC) were compared.
[0043] Figure 8 Results of lung examination of mice immunized with IL-21-Fc or IL-4-Fc mixed with RBD and aluminum adjuvant after intraperitoneal injection, specifically activated CD4 + T cells (CD69 + and PD1 + ) ratio comparison, activated CD8 + T cells (CD69 + and PD1 + ) ratio comparison.
[0044] Figure 9 shows the blood safety test results after intraperitoneal injection of IL-21-Fc mixed with RBD and aluminum adjuvant into immunized mice. Fig.9A Peripheral blood T cells (CD3 + 、CD4 + 、CD8 + ), B cells (CD19 + ) and NK cell ratio, Fig. 9B Results of serum inflammatory cytokine detection. DETAILED DESCRIPTION
[0045] The present invention is further described below with reference to examples and drawings, which may help researchers in the field understand, but the embodiments of the present invention are not limited thereto.
[0046] The following linearized pTT5 vector and RBD protein were obtained from the Structural Immunobiology Laboratory of the University of Science and Technology of China (preparation method refers to Weihong Zeng, et al., 2021), and Escherichia coli DH5α was purchased from Dingxiu Bio.
[0047] The following acetic acid, ethylenediaminetetraacetic acid (EDTA), Tris-base, hydrochloric acid (HCl), isopropanol, sodium hydroxide, sodium dodecyl sulfate (SDS), sodium chloride, potassium chloride, disodium hydrogen phosphate dodecahydrate, potassium hydrogen phosphate, Tween-20, concentrated sulfuric acid, etc. were purchased from Beijing Sinopharm Chemical Reagent Co., Ltd., Prime Star Max high-fidelity PCR enzyme was purchased from TAKARA, 0.22μm filter membrane, 0.45μm filter membrane, TMB colorimetric solution, Coomassie brilliant blue R250 were purchased from Biosharp, yeast extract and peptone were purchased from OXOID, 3KD / 10KD ultrafiltration concentration tube was purchased from Millipore, red blood cell lysis buffer and ampicillin antibiotic were purchased from Bio-Tech, DP117 endotoxin-free plasmid extraction kit was purchased from Tiangen Biochemical Technology Co., Ltd., protein Column A was purchased from Jinbaiao, 2×T5 exonuclease was purchased from Yisheng Bio, HRP-goat anti-mouse IgG secondary antibody, PCR primers and sequencing primers were purchased from Shanghai Shenggong, Union-293 culture medium was purchased from Yonglian Biotechnology Co., Ltd., high-protein skim high-calcium milk powder was purchased from Yili, F96MAXISORP NUNC-IMMUNO PLATE was purchased from Thermo Fisher Scientific, C57BL / 6 mice were purchased from Jicui Yaokang, mouse cDNA library was obtained by reverse transcription from C57BL / 6 mouse spleen, antibodies were purchased from Biotech, and aluminum hydroxide adjuvant was purchased from InvivoGen. PBS buffer and PBST buffer were prepared by themselves using the above-mentioned sodium chloride, potassium chloride, dipotassium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, and Tween-20. All other reagents not otherwise specified were commercially available.
[0048] Example 1 Construction of recombinant eukaryotic expression vector
[0049] The vectors pTT5-IL-21-Fc and pTT5-IL-4-Fc were constructed, wherein the vector pTT5-IL-21-Fc was as follows: Figure 1 As shown, the specific steps are as follows:
[0050] 1.PCR cloning and amplification of target fragment
[0051] The mouse IL-21 gene (Gene ID: 60505) has two transcript variants, of which the C-terminus (140-162) of transcript variant 1 is VCTLNAFLSLPCCVRVPPVPSDS, and the C-terminus (140-146) of transcript variant 2 is MIHQHLS, and the rest of the two variants are consistent; the mRNA of transcript variant 2 lacks 88bp of base sequence, and because it contains a stop codon, the amino acid sequence is frameshifted and the expression frame is postponed backward, ultimately shortening the amino acid sequence transcribed from variant 2 and producing a unique C-terminus.
[0052] Using mouse cDNA as template and mouse IL-21 gene transcript variant 1 for amplification, the full length could not be amplified.
[0053] Therefore, based on the mouse IL-21 gene sequence (Gene ID: 60505) transcript variant 2, as shown in SEQ ID NO: 3, primers were designed to have homologous segments of the linearized vector pTT5 at both ends:
[0054] Upstream primer:
[0055] AAGTCAAGCTGCTCTCTGGGCGTCGACCATAAATCAAGCCCCCA AGGGC;
[0056] Downstream primer:
[0057] GGAAATAAAGATTCTCAGAACCTCTAGAGGAGAGATGCTGATGA ATCATCTTTTGAAGG.
[0058] According to the mouse IL-4 gene sequence (Gene ID: 60505) transcript variant 2, as shown in SEQ ID NO: 6, primers were designed so that both ends of the primers contained homologous segments of the linearized vector pTT5:
[0059] Upstream primer:
[0060] AAGTCAAGCTGCTCTCTGGGCGTCGACCATATCCACGGATGCGA CAAAAATCAC
[0061] Downstream primer:
[0062] CCTTGGAAATAAAGATTCTCAGAACCTCTAGACGAGTAATCCAT TTGCATGATGCTCT
[0063] Using mouse cDNA as template, prepare 50 μL PCR reaction system:
[0064]
[0065] The PCR reaction conditions were:
[0066]
[0067]
[0068] Then, ②-④ were repeated for 30 cycles;
[0069] ⑤72℃ 10min;
[0070] ⑥4℃ 10min.
[0071] 2. Recovery of target fragment PCR product
[0072] PCR products were detected by 1% agarose gel electrophoresis at 120V for 35min. Figure 2 As shown, the PCR product corresponding to the band of about 442 pb in the fourth lane was recovered using the EZNACycle-Pure kit (Cat. No. D6492-02) of Omega Bio-Tek Company, and the operation steps were in accordance with the instruction manual.
[0073] 3. Construction, screening and identification of recombinant expression vectors
[0074] The concentration of the recovered PCR product was detected using a nucleic acid protein analyzer ScanDrop (ANALYTIKJENA, Germany), and the linearized vector pTT5 was connected by Gibson assembly at a ratio of 4:1. The connection system was as follows:
[0075]
[0076] Mix well and react at 50℃ for 60min.
[0077] Heat shock transformation, add 5 μL of ligation to 50 μL of competent DH5α, mix well and place on ice for 20 minutes, heat shock at 42°C for 75 seconds, place on ice for another 20 minutes, add 1 ml of sterilized LB medium without resistance, activate the bacteria at 37°C 200 rpm for 1 hour, centrifuge at 4000 rpm for 5 minutes to collect the bacteria, resuspend in 20 μL of LB medium without resistance, spread on LB / Amp plate, and incubate inverted in a biochemical incubator at 37°C overnight. Randomly select 5 monoclonal sequences the next day and save the strains. Figure 3 This is the sequencing result of the forward primer of pTT5-IL-21-Fc, which has no mismatches or gaps and is completely consistent with the designed virtual clone.
[0078] 4. Amplification and extraction of recombinant plasmid
[0079] Use the bacterial solution containing the correct sequence of pTT5-IL-21-Fc or pTT5-IL-4-Fc plasmid, take 10 μL of the bacterial solution and draw four lines on the LB / Amp plate, invert and culture at 37°C overnight to activate the bacteria, then inoculate a single clone into 250 mL 2TY / Amp medium and shake at 37°C 200 rpm for 16 h. The next day, use Tiangen's endotoxin-free plasmid extraction kit (Cat. No. DP117) to extract the plasmid, and use preheated ddH 2 After elution, store in a -20°C refrigerator.
[0080] Example 2 Obtaining fusion protein
[0081] 1. Transfection of pTT5-IL-21-Fc or pTT5-IL-4-Fc plasmid
[0082] The pTT5-IL-21-Fc or pTT5-IL-4-Fc plasmid obtained by the method of Example 1 was transfected into HEK293F cells (from Yonglian Biotechnology (Shanghai) Co., Ltd.) by transient transfection using a polymerizing agent, polyethyleneimine (PEI), so that the cells secreted IL-21-Fc protein or pTT5-IL-4-Fc protein into the culture medium. The specific steps are as follows:
[0083] HEK293F suspension cells were cultured to a cell density of 2 × 10 6 -3×10 6 / mL, with an activity rate of more than 95%.
[0084] For transfection, 0.1 mg plasmid, 0.4 mg PEI (1 mg / mL), and 5 mL DMEM high-glucose medium are required for each 100 mL HEK293F cell. DMEM is divided into two equal parts, and plasmid and PEI are added respectively. After mixing, stand at 37°C for 5 min. Pour the PEI mixture into the plasmid mixture, invert and mix, stand at 37°C for 20 min, and pour into HEK293F cells. Adjust the shaking parameters to 37°C, 0 rpm, and CO 2 The concentration was 5%, the humidity was 23%, and after standing for 30 minutes, the speed was changed to 120 rpm. Other conditions remained unchanged, and the protein was purified 4 days after transfection.
[0085] 2. Extraction of fusion protein IL-21-Fc or pTT5-IL-4-Fc
[0086] The HEK293F cell culture medium after the above transfection was used to collect the supernatant by centrifugation at 4°C and 5000rpm for 30min, and then filtered through a 0.22μm filter membrane. The fusion protein IL2-1-Fc was purified from the supernatant using a protein A column: the peristaltic pump flow rate was set to 3mL / min, and the protein A column was rinsed and balanced with pure water, 0.1M acetic acid, pure water, and PBS buffer in sequence. The supernatant after filtration was passed through the protein A column, and then the protein A column was connected to AKTA and eluted with 0.1M acetic acid. The UV peak of IL-21-Fc during the elution process is shown in the figure below: Figure 4A As shown, the SDS-PAGE electrophoresis results of the eluted IL-21-Fc protein are as follows Figure 4B As shown, the first lane is the protein marker, the second to sixth lanes are the fusion protein IL-21-Fc, and the predicted molecular weight of IL2-1-Fc is 43KDa, which is Figure 4B The strip sizes are basically consistent.
[0087] 3. Concentration and purification of IL2-1-Fc or pTT5-IL-4-Fc protein
[0088] Use a 10KDa concentrator to concentrate the eluted protein: add 10mL PBS buffer before using the concentrator, centrifuge at 3000rpm, balance the concentrator, and check for leaks; add the eluted protein and centrifuge at 3000rpm in a 4℃ centrifuge, replace the buffer with PBS, concentrate to 1ml, detect the concentration and mark, freeze in liquid nitrogen and store in a -80℃ refrigerator.
[0089] Example 3 Immunization of mice with aluminum adjuvant and fusion protein
[0090] The present invention uses the RBD region of the SARS-CoV-2 spike S protein (hereinafter referred to as RBD, the preparation method refers to Weihong Zeng, et al., 2021) as an antigen, and a mixture of an aluminum adjuvant and IL-21-Fc or pTT5-IL-4-Fc protein (obtained by the method of Example 2) as an adjuvant, immunizes mice by intraperitoneal injection, and then systematically evaluates the immunostimulatory effect of IL-21-Fc or pTT5-IL-4-Fc protein.
[0091] 5 μg RBD, 0.25 mg aluminum adjuvant and 1 mg IL-21-Fc or pTT5-IL-4-Fc protein were added to sterile PBS buffer, and the PBS buffer was supplemented to a total volume of 500 μL. The IL-21-Fc or pTT5-IL-4-Fc protein was stored in a -80 ° C refrigerator, and was quickly thawed before use and centrifuged at 12000 rpm 4 ° C for 10 min to remove the precipitate produced during the freeze-thaw process. C57BL / 6 mice (purchased from Jicui Yaokang) were intraperitoneally injected with 500 μL of the mixed solution on days 0, 14, and 28, and the mice were sacrificed on day 42 to detect the level of immune stimulation. PBS was the blank control group; RA was the control group, which was injected with the same dose of RBD and aluminum adjuvant as the experimental group; RA+IL-21 was experimental group 1, and each mouse was injected with 5μg RBD, 0.25mg aluminum adjuvant and 1mg IL-21-Fc protein; RA+IL-4 was experimental group 2, and each mouse was injected with 5μg RBD, 0.25mg aluminum adjuvant and 1mg IL-4-Fc protein.
[0092] Example 4 Detection of serum antigen-specific IgG levels
[0093] The method of Example 3 was used to obtain immunized mice, collect peripheral blood from the mice, centrifuge the peripheral blood at 4°C, 3000 rpm for 15 min to separate the layers, draw the upper light yellow serum, and detect the binding ability of IgG antibodies in the serum to RBD antigens. The specific steps are as follows:
[0094] Antigen RBD (2 μg / mL dissolved in 1× PBS buffer) was coated in 96-well NUNC-IMMUNO PLATE, 50 μL / well, at 4°C overnight.
[0095] After washing the coated antigen twice with 1×PBS, 200 μL of blocking solution (5% skim milk) was added to each well and incubated at room temperature for 2 h on a shaker at 100 rpm.
[0096] Use diluted serum as primary antibody, the starting concentration is 50-fold dilution, the dilution gradient is 3-fold, and there are 8 dilution gradients in total. The negative control is blocking solution. After washing away the blocking solution with 0.5% PBST buffer, add 100 μL of primary antibody to each well and incubate at room temperature for 1 hour on a shaker at 100 rpm.
[0097] After washing away the primary antibody with 0.5% PBST buffer, 100 μL of secondary antibody (goat anti-mouse IgG, prepared with a 1:5000 dilution in blocking solution) was added to each well and incubated at room temperature with a shaker at 100 rpm for 1 h.
[0098] After washing away the secondary antibody with 0.5% PBST, 100 μL TMB colorimetric solution was added to each well and incubated for 7 min in the dark. Then 50 μL 5% H 2 SO 4 Stop color development, detect OD450 value with microplate reader, and calculate serum antibody titer.
[0099] Antibody titer is an indicator used to measure the minimum concentration required for an antibody to recognize a specific antigen epitope (i.e., the maximum dilution factor that produces a positive value), which can reflect the affinity between the antibody and the antigen. Here, the positive value is set to 2.1 times that of the negative control. Figure 5 As shown, the serum antibody titer of the experimental group RA+IL-21 group was significantly higher than that of the control group RA (*, p<0.05) and the blank control group PBS (***, p<0.001). This indicates that IL-21-Fc fusion protein has an enhancing effect on the humoral immunity induced by the new crown RBD protein subunit vaccine.
[0100] Example 5 Detection of immune cell levels
[0101] The method of Example 3 can be used to obtain immunized mice, separate peripheral blood mononuclear cells (PBMC), lungs, spleens, and bone marrow of mice, and detect immune cell levels. The specific method is as follows:
[0102] Spleen: Grind the spleen of mice on a 200-mesh steel mesh and rinse with 1×PBS. Collect the cell filtrate, centrifuge at 800g for 5 min at 4°C, discard the supernatant, add 1 ml of red blood cell lysis buffer (purchased from Beyotime), leave at room temperature for 10 min, centrifuge again and discard the supernatant, resuspend the precipitate and label with antibodies, and detect by flow cytometry. Fig. 6A , Figure 6B As shown, compared with the control group RA, the addition of IL-21-Fc significantly increased the proportion of germinal center B cells (GCB) in the spleen (****, p<0.0001), the number of RBD-specific GCB cells was significantly increased compared with the control group (*, p<0.05), follicular helper T cells showed an increasing trend, and CD4 + T cells and CD8 + Compared with the control group RA, the addition of IL-4-Fc significantly increased the proportion of germinal center B cells (GCB) in the spleen (**, p<0.01), CD8 + T cell activation was significantly enhanced (**, p<0.01), while the number of RBD-specific GCB cells, follicular helper T cells, and CD4 + There was no significant difference in T cell activation.
[0103] Bone marrow: Take the mouse tibia, cut off both ends, use a 20ml syringe to absorb 1×PBS to flush, flush out the bone marrow, collect it in a 15ml centrifuge tube, centrifuge at 4℃ 800g for 5min, discard the supernatant, add 1ml red blood cell lysis buffer to resuspend, let it stand at room temperature for 5min, centrifuge again to discard the supernatant, resuspend the precipitate and label it with antibodies, and detect it by flow cytometry. The results are as follows Figure 7 As shown in the figure, the proportion of RBD-specific memory B cells (MBC) in the bone marrow of the RA+IL-21 group increased significantly (**, p<0.01), and there was no significant difference in plasma cells (PC) and plasmablasts (PB) compared with the control group RA, but there was a significant increase compared with the PBS blank control group. There was no significant difference in RBD-specific memory B cells (MBC), plasma cells (PC) and plasmablasts (PB) in the bone marrow of the RA+IL-4 group compared with the control group RA.
[0104] Lung: mince the lung, add 3ml 1mg / mL collagenase (purchased from Sigma-Aldrich), place in a shaker at 37℃200rpm for 40min, filter the digestion solution through a 200-mesh steel mesh, centrifuge at 4℃800g for 5min, discard the supernatant, add 3ml 40% Percoll separation solution for density gradient centrifugation, centrifuge at room temperature at 1260g, speed 6, speed 2 for 30min, discard the supernatant, add 1ml red blood cell lysis solution to resuspend, place at room temperature for 5min, centrifuge again and discard the supernatant, resuspend the precipitate and label it with antibodies, and detect it by flow cytometry. The results are as follows Figure 8 As shown, CD4+ T cells and CD8 + The proportion of PD1-positive cells in T cells was significantly higher than that in the control group RA (***, p<0.001), indicating that IL-21-Fc enhanced the activation of T cells in the lungs by the vaccine. + T cells and CD8 + There was no significant difference in the proportion of CD69 and PD1 positive cells in T cells compared with the control group RA.
[0105] In summary, IL-21-Fc fusion protein has an enhancing effect on the humoral immunity induced by the new coronavirus RBD protein subunit vaccine. The immune cell levels in the lungs, spleen, and bone marrow after administration were significantly higher than those after the administration of the new coronavirus RBD protein subunit vaccine without the addition of IL-21-Fc fusion protein. However, the effect of IL-4-Fc fusion protein on the humoral immunity induced by the new coronavirus RBD protein subunit vaccine was not obvious.
[0106] Example 6 Vaccine Safety Test
[0107] The method of Example 3 was used to obtain immunized mice, and peripheral blood mononuclear cells (PBMC) of mice were isolated: 1-2 drops of mouse peripheral blood (about 100 μL) were collected in EDTA anticoagulation Ep tubes, centrifuged at 4°C 800g for 5 min to separate the layers, the upper plasma was removed, 1 ml of red blood cell lysis solution was added and placed at room temperature for 15 min, centrifuged at 4°C 800g for 5 min, the supernatant was discarded, the precipitate was resuspended and labeled with antibodies, and the BD Fortessa analysis flow cytometer was used for detection. The results are shown in FIG. Fig.9A As shown, immune cells in peripheral blood, such as T cells (CD4 + T cells and CD8 + There was no significant change in the proportion of T cells, B cells, and NK cells, indicating that the addition of IL-21-Fc protein did not affect the safety of the vaccine.
[0108] The mouse serum obtained by the method of Example 3 was used to detect the changes of six cytokines (IL-6, IL-10, MCP-1, IFN-γ, TNF-α and IL-12p70) in the mouse serum using the BD Cytomertic Bead Array (CBA) Mouse Inflammation Kit (Cat. No.: 9256310). The specific steps were in accordance with the instructions of the kit. Fig. 9B As shown, there was no significant difference in the six cytokines among the PBS blank control, RA control group and RA+IL-21 experimental group, indicating that the addition of IL-21-Fc protein did not affect the safety of the vaccine.
[0109] Sequence Listing
[0110] SEQ ID NO:1 Upstream primer sequence of IL-21 gene fragment
[0111] AAGTCAAGCTGCTCTCTGGGCGTCGACCATAAATCAAGCCCCCAAGGGC
[0112] SEQ ID NO:2 Downstream primer sequence of IL-21 gene fragment
[0113] GGAAATAAAGATTCTCAGAACCTCTAGAGGAGAGATGCTGATGAATCATCTTTTG
[0114] AAGG
[0115] SEQ ID NO:3 Mouse IL-21 gene sequence
[0116] cataaatcaa gcccccaagg gccagatcgc ctcctgatta gacttcgtca ccttattgac
[0117] attgttgaac agctgaaaat ctatgaaaat gacttggatc ctgaacttct atcagctcca
[0118] caagatgtaa aggggcactg tgagcatgca gcttttgcct gttttcagaa ggccaaactc
[0119] aagccatcaa accctggaaa caataagaca ttcatcattg acctcgtggc ccagctcagg
[0120] aggaggctgc ctgccaggag gggaggaaag aaacagaagc acatagctaa atgcccttcc
[0121] tgtgattcgt atgagaaaag gacacccaaa gaattcctag aaagactaaa atggctcctt
[0122] caaaagatga ttcatcagca tctctcc
[0123] SEQ ID NO:4 Amino acid sequence of IL-21-Fc protein
[0124] HKSSPQGPDRLLIRLRHLIDIVEQLKIYENDLDPELLSAPQDVKGHCEHAAFACFQKA
[0125] KLKPSNPGNNKTFIIDLVAQLRRRLPARRGGKKQKHIAKCPSCDSYEKRTPKEFLERL
[0126] KWLLQKMIHQHLSSRGSENLYFQGSGSPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
[0127] KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
[0128] VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
[0129] KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
[0130] SEQ ID NO:5 Nucleotide sequence of IL-21-Fc protein
[0131] cataaatcaagcccccaagggccagatcgcctcctgattagacttcgtcaccttattgacattgttgaacagctgaaaatctatgaaaat
[0132] gacttggatcctgaacttctatcagctccacaagatgtaaaggggcactgtgagcatgcagcttttgcctgttttcagaaggccaaactc
[0133] aagccatcaaaccctggaaacaataagacattcatcattgacctcgtggcccagctcaggaggaggctgcctgccaggaggggag
[0134] gaaagaaacagaagcacatagctaaatgcccttcctgtgattcgtatgagaaaaggacacccaaagaattcctagaaagactaaaat
[0135] ggctccttcaaaagatgattcatcagcatctctcctctagaggttctgagaatctttatttccaaggttctggttctcccaaatcttgtgaca
[0136] aaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacacc
[0137] ctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtg
[0138] gacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcacc
[0139] gtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacca
[0140] tctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtca
[0141] gcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa
[0142] gaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcagggg
[0143] aacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaataa
[0144] SEQ ID NO:6 Mouse IL-4 gene sequence
[0145] catatccacggatgcgacaaaaatcacttgagagagatcatcggcattttgaacgaggtcacaggagaagggacgccatgcacgg
[0146] agatggatgtgccaaacgtcctcacagcaacgaagaacaccacagagtgagctcgtctgtagggcttccaaggtgcttcgcatat
[0147] tttatttaaaacatgggaaaactccatgcttgaagaagaactctagtgttctcatggagctgcagagactctttcgggcttttcgatgcct
[0148] ggattcatcgataagctgcaccatgaatgagtccaagtccacatcactgaaagacttcctggaaagcctaaagagcatcatgcaaatg
[0149] gattactcg
[0150] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
[0151] References
[0152] 1.Weihong Zeng,Huan Ma,Cheng chao Ding,et al.Characterization ofSARS-CoV-2-specific antibodies in COVID-19patients reveals highly potentneutralizing IgA,Signal Transduction and Targeted Therapy(2021)6:35.
Claims
1. Use of IL-21-Fc protein in preparing subunit vaccines, characterized in that: The amino acid sequence of IL-21-Fc protein is shown in SEQ ID NO:
4.
2. The use of claim 1, wherein the subunit vaccine is a SARS-CoV vaccine.
3. A method for preparing IL-21-Fc protein, characterized in that: The primer sequences for amplifying the IL-21-Fc gene fragment are: Upstream primer: AAGTCAAGCTGCTCTCTGGGCGTCGACCATAAATCAAGCCCCCA AGGGC; Downstream primer: GGAAATAAAGATTCTCAGAACCTCTAGAGGAGAGATGCTGATGA ATCATCTTTTGAAGG; The amino acid sequence of IL-21-Fc protein is shown in SEQ ID NO:
4.
4. The preparation method according to claim 3, characterized in that: The preparation method comprises obtaining the target IL-21 fragment by amplification, wherein the C-terminus of the target IL-21 fragment has an extracellular secretion signal peptide, and the N-terminus is connected to a TEV enzyme recognition site and an Fc tag.
5. An immune complex or subunit vaccine, characterized in that The invention comprises an antigen, an aluminum adjuvant and an IL-21-Fc protein, wherein the amino acid sequence of the IL-21-Fc protein is shown in SEQ ID NO:
4.
6. The immune complex or subunit vaccine of claim 5, wherein the antigen is the RBD region of the SARS-CoV-2 spike S protein.
7. The immune complex or subunit vaccine according to claim 5, wherein the aluminum adjuvant is aluminum hydroxide adjuvant.
8. The immune complex or subunit vaccine according to any one of claims 5 to 7, characterized in that The weight ratio of the antigen to the aluminum adjuvant to the IL-21-Fc protein is 1:50-100:
200.
9. The immune complex or subunit vaccine according to any one of claims 5 to 8, characterized in that The immune complex or subunit vaccine is administered three times, with an interval of 14 days between administrations.
10. A kit comprising the immune complex or subunit vaccine according to any one of claims 5 to 9.
